Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.

Original publication

DOI

10.1016/j.virol.2012.08.033

Type

Journal article

Journal

Virology

Publication Date

25/11/2012

Volume

433

Pages

410 - 420

Keywords

Adult, Antibodies, Neutralizing, Antibody Specificity, Antigenic Variation, CD4 Lymphocyte Count, Chronic Disease, Disease Progression, Epitope Mapping, Female, HIV Antibodies, HIV Antigens, HIV Infections, HIV-1, Humans, Immunoglobulin G, Male, Middle Aged, Receptors, IgG, Retrospective Studies, Viral Load, Young Adult